cleavage and polyadenylation specific factor 6Genealiases: CFIM · CFIM68 · CFIM72 · HPBRII-4 · HPBRII-7
Q-omics provides the consensus-scored CPSF6 profile across patient tissues and cancer cell-line models. CPSF6 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, CPSF6 is differentially expressed in 16, with the highest sampling consensus in BLCA. Additionally, CPSF6 protein abundance shows 29,307 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight LIHC, BLCA, and LSCC as cancer lineages where CPSF6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CPSF6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CPSF6 survival associations across molecular data types. CPSF6 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (7) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CPSF6 RNA expression–survival associations across cancer types. High CPSF6 expression shows unfavorable associations in LIHC, ACC, MESO and KIRP, but favorable associations in UCS and BRCA. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for CPSF6 RNA expression.
This table summarizes CPSF6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 6. The strongest signals are observed in BLCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for CPSF6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CPSF6 shows higher tumor expression in BLCA, HNSC, COAD, LIHC, STAD and LUAD. The BLCA box plot shows higher CPSF6 RNA expression in tumor versus normal tissue (log2 FC = +0.870, t-test p < 0.001).
This table shows molecular features associated with CPSF6 in patient tissues and cancer cell lines. In patient samples, CPSF6 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, CPSF6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BONE and UPPER_AERODIGESTIVE_TRACT.
